EuroSIDA Newsletter

September 2026

Dear EuroSIDA Study Investigators,

The EuroSIDA Coordinating Centre sends late warm summer greetings to all our collaborators. We deeply appreciate your ongoing commitment and support to EuroSIDA. We are pleased to share the latest updates from the EuroSIDA network, including progress from ongoing cohorts, upcoming meetings and conferences and study milestones.

Study Updates

Dataset 53

Dataset 53 (Autumn 2025) was sent to almost 90 sites in 34 countries. Approximately **8,900 of 9,200 REDCap follow-up forms** were completed, and **REST follow-up data** have been received from approximately **2,000 participants**. In total, we have received data from more than 11,000 participants. The data cleaning process is now complete, and the final dataset is ready for analyses.

We would like to thank all participating sites for their continued support and flexibility throughout this data collection period.

Dataset 54

Dataset 54 opened on **September 1 for REST** sites and will **October 1 for REDCap sites.** All sites will receive a cover letter package with the relevant study materials. As in previous years, we encourage sites to submit data as early as possible to allow sufficient time for data review and quality checks.

The deadline for data submission is **1st December 2026**. We look forward to another successful data collection round with your continued support.

Update from the EuroSIDA Long-acting Cabotegravir + Rilpivirine Study

Enrolment was completed for the new cohort investigating uptake and outcomes of long-acting Cabotegravir+Rilpivirine (LA CBV+RPV) with the support of ViiV Healthcare and the EuroSIDA Steering Committee. To date, we have **1,026 participants** (288 EuroSIDA and 738 non-EuroSIDA) included, who started CAB+RPV LA therapy prior to 31 December 2025. The 1,026 participants were enrolled from 46 EuroSIDA sites across 18 countries. This important contribution would not have been possible without the commitment of the participating EuroSIDA sites, and we would like to thank all sites for their contribution to the cohort.

In total, sites to date contributed **2,562** person-years of follow-up to the study, with a median follow-up time of 31 months (IQR 18-36) per person. The median number of CAB+RPV injections was 11 (IQR 4-18) per person. For a full overview of participant demographics, see Table 1.

Table 1. **Demographics of CAB+RPV LA participants**

	N=1026
Sex/gender: Males, n (%)	836 (81.5%)
Age, median (IQR)	47 (37-56)
HIV acquisition mode, n (%)	
MSM	677 (66.0%)
People who inject(ed) drugs	60 (5.9%)
Heterosexual	225 (21.9%)
Other/unknown	64 (6.2%)
Race/ethnicity, n (%)	
White	733 (71.4%)
Black	109 (10.6%)
Other	56 (5.5%)
Unknown/prohibited	128 (12.5%)
EuroSIDA region, n (%)	
South	368 (35.9%)
Central West	315 (30.7%)
North	210 (20.5%)
Central East	133 (13.0%)

Approximately one third of participants were enrolled in the South region, with the majority starting CAB+RPV LA from 2023 onwards (see Figure 1). The Central West region also enrolled around a third with most starting treatment from 2021 onwards. Only a small number started CAB+RPV LA as part of a clinical trial prior to the EMA approval date in December 2020. No participants were included from East Europe.

Figure 1. **Number of participants starting CAB+RPV LA according to year and region**



Looking ahead, the second Follow-up (FU2) in REDCap is scheduled to begin on **1 October 2026.**

EuroSIDA has successfully secured funding for the continuation of the CAB+RPV LAI cohort until 2030 in collaboration with ViiV Healthcare and the EuroSIDA Steering Committee. This includes funding to enroll additional 500 EuroSIDA and non-EuroSIDA participants initiating CAB+RPV LAI after 1 January 2026. This will enable EuroSIDA to expand our current CAB+ RPV LA research agenda to also include long-term discontinuation rates, resistance, potential adverse outcomes, and compare with other oral cotemporary treatment regimens.

The enrolment process will start in January 2027 with retrospective data

collection from January 2026.

EuroSIDA-MISTRAL

The EU funding ended in December 2025 by which date we had visit 1 data from 991 participants and visit 2 data from 795. We are currently applying for funding for an extension until 2030. The extension will include annual clinical follow-up forms and potentially an annual collection of samples (plasma and serum) and questionnaires. The upcoming clinical follow-up (MISTRAL Follow-up 4) will open as planned on 1st October 2026 and close in December 2026.

With a substantial body of data now collected and analysed, we are advancing the development of EuroSIDA-MISTRAL publications. Our team is currently focused on the following manuscripts:

- **Real-time monitoring of REDCap data using R Markdown to increase data quality and ease quality assurance.** As part of the MISTRAL study, we set up R code to create an HTML-based, interactive data quality report that can be used to monitor real-time incoming data across multiple REDCap projects and additional data sources. **Status: submitted to BMC Medical Research Methodology.**
- **EuroSIDA-MISTRAL Cohort Profile.** A descriptive manuscript describing the EuroSIDA-MISTRAL cohort and the set-up of the study. **Status: producing first draft.**
- **Gut dysbiosis is associated with elevated systemic inflammation and cardiovascular risk in ageing people with HIV.** A manuscript presenting clinical and microbiome findings from baseline analyses. **Status: producing first draft.**

RESPOND

EuroSIDA continues to be the largest contributor to the RESPOND cohort consortium. EuroSIDA is represented in both the RESPOND Executive Committee and the Scientific Steering Committee.

For full overview of all RESPOND presentations and publications, please see the RESPOND website. To stay updated on ongoing and upcoming research activities, follow RESPOND on **the website**.

EuroSIDA Investigator Meeting in Glasglow, November 2026

EuroSIDA investigator meeting will take place during the **Glasgow Conference held in Glasgow from 8-11 November 2026.**

The meeting will be held on **November 9** and will provide an opportunity for investigators and collaborators to come together, discuss ongoing research activities and share updates across the EuroSIDA network. These annual meetings remain an important part of fostering collaboration, exchanging ideas and strengthening our research community. ***Invitations have been sent to all investigators. Please let us know if you plan to attend, so we can send you an Outlook calendar invitation.***

We look forward to seeing you in Glasgow for another productive and engaging meeting!

Reimbursement

The reimbursement process for Dataset 53 is almost complete. All REDCap sites have received payment, and reimbursement process for REST sites is almost complete. Please reach out to the coordinating centre if you have any questions about this.

Message from Friends: WEEPI foundation

Our friends at the WEEPI Foundation have asked us to share that the call for applications for Seed Grants: 1 year 30,000 CHF – is open. See more here: **https://weepi.org/apply/**

Reminders

Data Processing Agreement (DPA)

As plasma sampling has been discontinued from 1 August 2025, all ongoing DPA-related procedures have been discontinued.

Regulatory Approvals

We kindly urge you to keep us informed of any updates or progress from your respective ethics committees.

Staff Changes

Please inform us of any changes in staff or principal investigators at your site. This will allow us to update the study group and database accordingly.

EuroSIDA Publications

The EuroSIDA study has reached **358 publications!**

Publications in 2026 so far: 2

1. **Trends in AIDS-defining illnesses among people living with HIV in clinical care in Europe: results from the EuroSIDA multicentre cohort study (2003-2024).**
   Bannister WP, Reekie J, Peters L, et al; EuroSIDA Study Group.
   Lancet HIV. 2026 May

2. **Stability of the HIV cascade of care throughout the COVID-19 pandemic in Europe: results from the multinational EuroSIDA cohort study (2016–2022)**
   Bannister WP et al. HIV Med 2026

In collaboration with RESPOND

1. **Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborations.** *Han WM et al.*
   EClinicalMedicine. 2026

2. **Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implications.** *Kraef C et al.*
   Eur Respir J. 2026;67(3)

3. **CD4 Cell Count Trends After the Common Cancers in People With HIV: A Multicohort Collaboration**. *Timiryasova A et al.*
   AIDS. 2026 July 7

4. **Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND.** *Surial B et al.*
   Open Forum Infect Dis. 2026 Aug 6;13(8)

All EuroSIDA publications can be found **here**.

We hope everyone in EuroSIDA study is doing well! The success of EuroSIDA relies on the dedication and contribution of all participating investigators and sites. We greatly appreciate your ongoing efforts.

EuroSIDA

Why are you receiving this email?

You are receiving this email because you are affiliated with the EuroSIDA study. By providing your contact details to the EuroSIDA Coordinating Centre, you are included in the mailing list for the EuroSIDA study.

Contact

Please always feel free to contact the EuroSIDA coordinating centre at **eurosida.rigshospitalet@regionh.dk**.
No question is too small or too big, we are happy to assist in all matters!

EuroSIDA Coordinating Centre
Rigshospitalet
CHIP, Section 2100
Blegdamsvej 9 · DK-2100 Copenhagen Ø · Denmark